Annual CFF
-$6.21 M
+$22.18 M+78.13%
December 31, 2022
Summary
- As of February 8, 2025, EGRX annual cash flow from financing activities is -$6.21 million, with the most recent change of +$22.18 million (+78.13%) on December 31, 2022.
- During the last 3 years, EGRX annual CFF has risen by +$18.02 million (+74.37%).
- EGRX annual CFF is now -111.12% below its all-time high of $55.81 million, reached on December 31, 2015.
Performance
EGRX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$6.41 M
-$19.06 M-150.70%
June 30, 2023
Summary
- As of February 8, 2025, EGRX quarterly cash flow from financing activities is -$6.41 million, with the most recent change of -$19.06 million (-150.70%) on June 30, 2023.
- Over the past year, EGRX quarterly CFF has dropped by -$5.88 million (-1096.08%).
- EGRX quarterly CFF is now -105.99% below its all-time high of $107.06 million, reached on March 31, 2020.
Performance
EGRX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$11.92 M
-$5.88 M-33.01%
June 30, 2023
Summary
- As of February 8, 2025, EGRX TTM cash flow from financing activities is $11.92 million, with the most recent change of -$5.88 million (-33.01%) on June 30, 2023.
- Over the past year, EGRX TTM CFF has increased by +$43.97 million (+137.20%).
- EGRX TTM CFF is now -86.06% below its all-time high of $85.49 million, reached on March 31, 2020.
Performance
EGRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
EGRX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +78.1% | -1096.1% | +137.2% |
| 3 y3 years | +74.4% | +94.4% | +190.8% |
| 5 y5 years | -176.6% | -488.2% | +149.2% |
EGRX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +78.1% | -150.7% | +43.6% | -33.0% | +132.4% |
| 5 y | 5-year | at high | +83.6% | -106.0% | +94.4% | -86.1% | +108.1% |
| alltime | all time | -111.1% | +93.0% | -106.0% | +94.4% | -86.1% | +108.1% |
Eagle Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2023 | - | -$6.41 M(-150.7%) | $11.92 M(-33.0%) |
| Mar 2023 | - | $12.65 M(+429.3%) | $17.80 M(-386.6%) |
| Dec 2022 | -$6.21 M(-78.1%) | $2.39 M(-27.5%) | -$6.21 M(-66.8%) |
| Sep 2022 | - | $3.30 M(-714.9%) | -$18.71 M(-41.6%) |
| Jun 2022 | - | -$536.00 K(-95.3%) | -$32.05 M(-12.8%) |
| Mar 2022 | - | -$11.36 M(+12.3%) | -$36.73 M(+29.4%) |
| Dec 2021 | -$28.39 M(-25.0%) | -$10.11 M(+0.8%) | -$28.39 M(+16.4%) |
| Sep 2021 | - | -$10.04 M(+92.3%) | -$24.39 M(-36.3%) |
| Jun 2021 | - | -$5.22 M(+72.8%) | -$38.31 M(-74.1%) |
| Mar 2021 | - | -$3.02 M(-50.6%) | -$147.94 M(+290.7%) |
| Dec 2020 | -$37.87 M(+56.3%) | -$6.12 M(-74.5%) | -$37.87 M(+5.6%) |
| Sep 2020 | - | -$23.96 M(-79.1%) | -$35.86 M(+173.1%) |
| Jun 2020 | - | -$114.85 M(-207.3%) | -$13.13 M(-115.4%) |
| Mar 2020 | - | $107.06 M(-2707.9%) | $85.49 M(-452.9%) |
| Dec 2019 | -$24.23 M(-72.5%) | -$4.11 M(+234.6%) | -$24.23 M(-65.7%) |
| Sep 2019 | - | -$1.23 M(-92.4%) | -$70.58 M(-14.0%) |
| Jun 2019 | - | -$16.24 M(+511.3%) | -$82.03 M(+22.6%) |
| Mar 2019 | - | -$2.66 M(-94.7%) | -$66.88 M(-24.1%) |
| Dec 2018 | -$88.12 M(-1187.3%) | -$50.46 M(+298.1%) | -$88.12 M(+101.5%) |
| Sep 2018 | - | -$12.68 M(+1062.9%) | -$43.73 M(-1013.4%) |
| Jun 2018 | - | -$1.09 M(-95.4%) | $4.79 M(-226.4%) |
| Mar 2018 | - | -$23.89 M(+293.0%) | -$3.79 M(-146.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2017 | $8.10 M(-124.1%) | -$6.08 M(-117.0%) | $8.10 M(-290.9%) |
| Sep 2017 | - | $35.85 M(-470.9%) | -$4.25 M(-92.3%) |
| Jun 2017 | - | -$9.66 M(-19.4%) | -$55.33 M(+21.2%) |
| Mar 2017 | - | -$12.00 M(-34.9%) | -$45.67 M(+35.6%) |
| Dec 2016 | -$33.67 M(-160.3%) | -$18.43 M(+20.9%) | -$33.67 M(+126.7%) |
| Sep 2016 | - | -$15.24 M(<-9900.0%) | -$14.86 M(-3948.4%) |
| Jun 2016 | - | $0.00(0.0%) | $386.00 K(-30.2%) |
| Mar 2016 | - | $0.00(-100.0%) | $553.00 K(-99.0%) |
| Dec 2015 | $55.81 M(+20.9%) | $386.00 K(>+9900.0%) | $55.81 M(+0.6%) |
| Sep 2015 | - | $0.00(-100.0%) | $55.46 M(-0.1%) |
| Jun 2015 | - | $167.00 K(-99.7%) | $55.53 M(+1.1%) |
| Mar 2015 | - | $55.26 M(>+9900.0%) | $54.94 M(+17.7%) |
| Dec 2014 | - | $34.00 K(-47.8%) | $46.69 M(+1.2%) |
| Sep 2014 | $46.15 M(+370.5%) | $65.10 K(-115.6%) | $46.15 M(+0.2%) |
| Jun 2014 | - | -$418.20 K(-100.9%) | $46.07 M(-18.3%) |
| Mar 2014 | - | $47.01 M(-9538.8%) | $56.40 M(+505.7%) |
| Dec 2013 | - | -$498.00 K(+2427.9%) | $9.31 M(-5.1%) |
| Sep 2013 | $9.81 M(+2.7%) | -$19.70 K(-100.2%) | $9.81 M(-0.2%) |
| Jun 2013 | - | $9.91 M(<-9900.0%) | $9.83 M(<-9900.0%) |
| Mar 2013 | - | -$82.50 K(<-9900.0%) | -$82.50 K(<-9900.0%) |
| Dec 2012 | - | $0.00 | $0.00 |
| Sep 2012 | $9.55 M | - | - |
FAQ
- What is Eagle Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Eagle Pharmaceuticals?
- What is Eagle Pharmaceuticals annual CFF year-on-year change?
- What is Eagle Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Eagle Pharmaceuticals?
- What is Eagle Pharmaceuticals quarterly CFF year-on-year change?
- What is Eagle Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Eagle Pharmaceuticals?
- What is Eagle Pharmaceuticals TTM CFF year-on-year change?
What is Eagle Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of EGRX is -$6.21 M
What is the all time high annual CFF for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high annual cash flow from financing activities is $55.81 M
What is Eagle Pharmaceuticals annual CFF year-on-year change?
Over the past year, EGRX annual cash flow from financing activities has changed by +$22.18 M (+78.13%)
What is Eagle Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of EGRX is -$6.41 M
What is the all time high quarterly CFF for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high quarterly cash flow from financing activities is $107.06 M
What is Eagle Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, EGRX quarterly cash flow from financing activities has changed by -$5.88 M (-1096.08%)
What is Eagle Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of EGRX is $11.92 M
What is the all time high TTM CFF for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high TTM cash flow from financing activities is $85.49 M
What is Eagle Pharmaceuticals TTM CFF year-on-year change?
Over the past year, EGRX TTM cash flow from financing activities has changed by +$43.97 M (+137.20%)